ArticlePloS one2015
Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Dual roles of IL-18 in colitis through regulation of the function and quantity of goblet cells.International journal of molecular medicine · 2019Pooled it
- Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.The pharmacogenomics journal · 2017Pooled it
- Aquamin, a marine derived multi-mineral, attenuates toll-like receptor-mediated inflammatory responses in macrophages.Frontiers in immunology · 2026Article
- Main genetic factors associated with inflammatory bowel diseases and their consequences on intestinal permeability: involvement in gut inflammation.Journal of gastroenterology · 2025Review
- Mucosal Responses to Type II Interferon in IBD.Inflammatory bowel diseases · 2025Article
- Decursin-Loaded Nanovesicles Target Macrophages Driven by the Pathological Process of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Genetic Polymorphisms ofArchives of Razi Institute · 2023Article
- Inflammation, microbiome and colorectal cancer disparity in African-Americans: Are there bugs in the genetics?World journal of gastroenterology · 2022Review
- The Roles of IL-17, IL-21, and IL-23 in theToxins · 2021Review
- Potential Effects of Nutraceuticals in Retinopathy of Prematurity.Life (Basel, Switzerland) · 2021Review
- Role of the IL23/IL17 Pathway in Crohn's Disease.Frontiers in immunology · 2021Review
- Interleukin-12B gene rs6887695 and rs2288831 polymorphisms are associated with an increased risk of ulcerative colitis development in Chinese Han population: A case-control study.Journal of clinical laboratory analysis · 2020Article
- Inflammatory Bowel Diseases: Host-Microbial-Environmental Interactions in Dysbiosis.Diseases (Basel, Switzerland) · 2020Review
- NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium.Scientific reports · 2020Article
- Review
- All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective.ImmunoTargets and therapy · 2020Review
- Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis.BMC medical genetics · 2018Article
- Neonatal selection by Toll-like receptor 5 influences long-term gut microbiota composition.Nature · 2018Article
- Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.The pharmacogenomics journal · 2018Article
- Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), result from the combined effects of susceptibility genes and environmental factors. Previous studies have shown that polymorphisms in the Toll-like receptor (TLR), the apoptosis, the IL-23/IL-17 and the interferon gamma (IFNG) pathways are associated with risk of both CD and UC.
methodsUsing a candidate gene approach, 21 functional single nucleotide polymorphisms (SNPs) in 15 genes were assessed in a clinical homogeneous group of severely diseased ethnic Danish patients consisting of 624 patients with CD, 411 patients with UC and 795 controls. The results were analysed using logistic regression.
resultsThe polymorphisms TLR5 (rs5744174) and IL12B (rs6887695) were associated with risk of CD, and TLR1 (rs4833095) and IL18 (rs187238) were associated with risk of both CD and UC (p<0.05). After Bonferroni correction for multiple testing, the homozygous variant genotype of TLR1 743 T>C (rs4833095) was associated with increased risk CD (OR: 3.15, 95% CI: 1.59-6.26, p = 0.02) and CD and UC combined (OR: 2.96, 95% CI: 1.64-5.32, p = 0.005).
conclusionOur results suggest that genetically determined high activity of TLR1 and TLR5 was associated with increased risk of both CD and UC and CD, respectively. This supports that the host microbial composition or environmental factors in the gut are involved in risk of IBD. Furthermore, genetically determined high activity of the IL-23/IL-17 pathway was associated with increased risk of CD and UC. Overall, our results support that genetically determined high inflammatory response was associated with increased risk of both CD and UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.